- Home
- OPFI vs TVRD Comparison
OPFI vs TVRD Comparison
Compare OPFI & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPFI
- TVRD
- Stock Information
- Founded
- OPFI 2009
- TVRD 2017
- Country
- OPFI United States
- TVRD United States
- Employees
- OPFI N/A
- TVRD N/A
- Industry
- OPFI Finance: Consumer Services
- TVRD Biotechnology: Pharmaceutical Preparations
- Sector
- OPFI Finance
- TVRD Health Care
- Exchange
- OPFI Nasdaq
- TVRD Nasdaq
- Market Cap
- OPFI 288.7M
- TVRD 246.5M
- IPO Year
- OPFI N/A
- TVRD N/A
- Fundamental
- Price
- OPFI $9.94
- TVRD $4.22
- Analyst Decision
- OPFI Buy
- TVRD Buy
- Analyst Count
- OPFI 2
- TVRD 7
- Target Price
- OPFI $11.75
- TVRD $51.67
- AVG Volume (30 Days)
- OPFI 840.3K
- TVRD 718.4K
- Earning Date
- OPFI 10-29-2025
- TVRD 11-21-2025
- Dividend Yield
- OPFI 2.58%
- TVRD N/A
- EPS Growth
- OPFI N/A
- TVRD N/A
- EPS
- OPFI 0.14
- TVRD N/A
- Revenue
- OPFI $335,437,000.00
- TVRD N/A
- Revenue This Year
- OPFI $119.75
- TVRD N/A
- Revenue Next Year
- OPFI $10.98
- TVRD N/A
- P/E Ratio
- OPFI $71.62
- TVRD N/A
- Revenue Growth
- OPFI 28.69
- TVRD N/A
- 52 Week Low
- OPFI $4.83
- TVRD $4.40
- 52 Week High
- OPFI $17.73
- TVRD $43.65
- Technical
- Relative Strength Index (RSI)
- OPFI 44.49
- TVRD 19.30
- Support Level
- OPFI $9.00
- TVRD $4.63
- Resistance Level
- OPFI $10.33
- TVRD $5.00
- Average True Range (ATR)
- OPFI 0.51
- TVRD 0.40
- MACD
- OPFI 0.02
- TVRD 0.40
- Stochastic Oscillator
- OPFI 34.45
- TVRD 1.02
About OPFI OppFi Inc.
OppFi Inc is a tech-enabled, mission-driven specialty finance platform that broadens the reach of community banks to extend credit access to everyday Americans. It recognizes revenue through finance charges on installment and SalaryTap contracts based on the interest method.
About TVRD Tvardi Therapeutics Inc. Common Stock
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.